The global xerostomia therapeutics market accounted for USD 2.25 billion in 2023 and is expected to reach at USD 3.69 billion by 2034 with a CAGR of 4.61% during the forecast period 2024-2034. Rise in chemotherapy & radiotherapy utilization for cancer treatment, increasing prevalence of xerostomia among the elderly, growing reliance on prescribed medications, expanding prevalence of conditions such as Parkinson’s disease, hypertension, & diabetes, heightened awareness regarding products addressing xerostomia, ongoing research & development efforts aimed at developing more effective solutions, and surge in the introduction of innovative therapeutics for xerostomia are some of the drivers driving the market growth.
Surge in the introduction of innovative therapeutics for xerostomia is predicted to boost the market growth during the forecast period. Xerostomia is characterized by oral dryness resulting primarily from decreased saliva production. It can manifest as a dry mouth sensation, oral burning, swallowing difficulties, or diminished taste sensation. Common causes include medication side effects, head and neck radiation therapy, and chemotherapy, as well as potential association with Sjogren’s syndrome. For instance, in May 2023, Rapid Dose Therapeutics introduced a topical lidocaine strip and a dissolving dry mouth treatment in Canada. Leveraging its QuickStrip technology, LQS offers a thin film of lidocaine, which dentists can apply as a topical numbing agent prior to administering local anesthesia injections. Additionally, the company's technology is employed in XyliStrip, an oral dissolving thin film strip designed for managing xerostomia.
By type, OTC was the highest revenue-grossing segment in the global xerostomia therapeutics market in 2023 owing to the extensive range & accessibility, safety & effectiveness of over-the-counter (OTC) products, combined with the limited availability of branded drugs and their affordability, make them the primary treatment option for xerostomia. The majority of cases can be managed with OTC products without encountering complications. Additionally, prescription is predicted to grow at the fastest CAGR during the forecast period owing to the rising occurrence of xerostomia, increasing reliance on prescription medication for severe cases, and surge in the introduction of new products. For instance, in July 2023, K Pharmaceuticals is excited to introduce Aquoral, an oral spray clinically validated for Dry Mouth, also known as Xerostomia. This condition, often debilitating, can be caused by various factors such as illness, medication side effects, or other reasons, leading to discomfort and potentially impacting chewing, tasting, swallowing, and speaking abilities.
By product, salivary stimulants was the highest revenue-grossing segment in the global xerostomia therapeutics market in 2023 owing to the increasing release of new products and surge in number of clinical trials being conducted. Salivary stimulants are agents capable of boosting saliva production. For instance, in June 2023, MeiraGTx Holdings plc, a vertically integrated gene therapy company in the clinical stage, has reported encouraging clinical findings from the concluded Phase 1 AQUAx trial of AAV2-hAQP1, aimed at addressing grade 2/3 radiation-induced xerostomia (RIX). Additionally, dentifrices is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on innovating new toothpaste, gel, & mouthwash formulations. These specialized dental hygiene products, including cleaning agents, powders, or pastes, are designed to alleviate dry mouth by removing irritants that contribute to its occurrence.
By distribution channel, online pharmacy was the highest revenue-grossing segment in the global xerostomia therapeutics market in 2023 owing to the various advantages provided by mail order pharmacies including medication delivery to homes, discounts through health plans, specialized consumer services, convenient prescription refills, and increasing partnerships among major industry participants. For instance, in April 2023, 3M Health Information Systems has partnered with Amazon Web Services (AWS) to speed up the development and progress of 3M M Modal ambient intelligence. In this partnership, 3M will utilize AWS Machine Learning (ML) and generative AI services, including Amazon Comprehend Medical, Amazon Bedrock, and Amazon Transcribe Medical, to expedite, improve, and broaden the implementation of 3M's ambient clinical documentation and virtual assistant solutions. This will contribute to the company's business expansion efforts. Additionally, hospital pharmacies is predicted to grow at the fastest CAGR during the forecast period owing to the growing prevalence of xerostomia and increasing demand for novel treatment options.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising incidence of xerostomia & related dry mouth conditions such as Sjogren’s syndrome & rheumatoid arthritis and increase in initiatives aimed at raising awareness about dry mouth. For instance, in April 2023, The Sjogren’s Foundation has initiated efforts to raise awareness about Sjogren’s syndrome through the establishment of the April is Sjogren’s Awareness Month campaign. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in research & development endeavors, rise in the occurrence of diabetes, cancer, & Parkinson's disease, and increase in collaborations among market participants. For instance, in October 2022, For the inaugural occasion, Haleon Group of Companies extended invitations to consumer health startups in India to collaborate with Re/Wire Health Studio, an innovative global partnership platform introduced by Haleon NEXT, the forward-thinking innovation division of the multinational consumer health company Haleon. This initiative has facilitated the company's expansion on a global scale.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Surge in the introduction of innovative therapeutics for xerostomia is predicted to boost the market growth during the forecast period. Xerostomia is characterized by oral dryness resulting primarily from decreased saliva production. It can manifest as a dry mouth sensation, oral burning, swallowing difficulties, or diminished taste sensation. Common causes include medication side effects, head and neck radiation therapy, and chemotherapy, as well as potential association with Sjogren’s syndrome. For instance, in May 2023, Rapid Dose Therapeutics introduced a topical lidocaine strip and a dissolving dry mouth treatment in Canada. Leveraging its QuickStrip technology, LQS offers a thin film of lidocaine, which dentists can apply as a topical numbing agent prior to administering local anesthesia injections. Additionally, the company's technology is employed in XyliStrip, an oral dissolving thin film strip designed for managing xerostomia.
By type, OTC was the highest revenue-grossing segment in the global xerostomia therapeutics market in 2023 owing to the extensive range & accessibility, safety & effectiveness of over-the-counter (OTC) products, combined with the limited availability of branded drugs and their affordability, make them the primary treatment option for xerostomia. The majority of cases can be managed with OTC products without encountering complications. Additionally, prescription is predicted to grow at the fastest CAGR during the forecast period owing to the rising occurrence of xerostomia, increasing reliance on prescription medication for severe cases, and surge in the introduction of new products. For instance, in July 2023, K Pharmaceuticals is excited to introduce Aquoral, an oral spray clinically validated for Dry Mouth, also known as Xerostomia. This condition, often debilitating, can be caused by various factors such as illness, medication side effects, or other reasons, leading to discomfort and potentially impacting chewing, tasting, swallowing, and speaking abilities.
By product, salivary stimulants was the highest revenue-grossing segment in the global xerostomia therapeutics market in 2023 owing to the increasing release of new products and surge in number of clinical trials being conducted. Salivary stimulants are agents capable of boosting saliva production. For instance, in June 2023, MeiraGTx Holdings plc, a vertically integrated gene therapy company in the clinical stage, has reported encouraging clinical findings from the concluded Phase 1 AQUAx trial of AAV2-hAQP1, aimed at addressing grade 2/3 radiation-induced xerostomia (RIX). Additionally, dentifrices is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on innovating new toothpaste, gel, & mouthwash formulations. These specialized dental hygiene products, including cleaning agents, powders, or pastes, are designed to alleviate dry mouth by removing irritants that contribute to its occurrence.
By distribution channel, online pharmacy was the highest revenue-grossing segment in the global xerostomia therapeutics market in 2023 owing to the various advantages provided by mail order pharmacies including medication delivery to homes, discounts through health plans, specialized consumer services, convenient prescription refills, and increasing partnerships among major industry participants. For instance, in April 2023, 3M Health Information Systems has partnered with Amazon Web Services (AWS) to speed up the development and progress of 3M M Modal ambient intelligence. In this partnership, 3M will utilize AWS Machine Learning (ML) and generative AI services, including Amazon Comprehend Medical, Amazon Bedrock, and Amazon Transcribe Medical, to expedite, improve, and broaden the implementation of 3M's ambient clinical documentation and virtual assistant solutions. This will contribute to the company's business expansion efforts. Additionally, hospital pharmacies is predicted to grow at the fastest CAGR during the forecast period owing to the growing prevalence of xerostomia and increasing demand for novel treatment options.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising incidence of xerostomia & related dry mouth conditions such as Sjogren’s syndrome & rheumatoid arthritis and increase in initiatives aimed at raising awareness about dry mouth. For instance, in April 2023, The Sjogren’s Foundation has initiated efforts to raise awareness about Sjogren’s syndrome through the establishment of the April is Sjogren’s Awareness Month campaign. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in research & development endeavors, rise in the occurrence of diabetes, cancer, & Parkinson's disease, and increase in collaborations among market participants. For instance, in October 2022, For the inaugural occasion, Haleon Group of Companies extended invitations to consumer health startups in India to collaborate with Re/Wire Health Studio, an innovative global partnership platform introduced by Haleon NEXT, the forward-thinking innovation division of the multinational consumer health company Haleon. This initiative has facilitated the company's expansion on a global scale.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Product, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
Segmentation: Xerostomia Therapeutics Market Report 2023 - 2034
Xerostomia Therapeutics Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Prescription
- OTC
Xerostomia Therapeutics Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Dentifrices
- Salivary Substitutes
- Salivary Stimulants
Xerostomia Therapeutics Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Xerostomia Therapeutics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Xerostomia Therapeutics Market: Type Estimates & Trend Analysis
8. Xerostomia Therapeutics Market: Product Estimates & Trend Analysis
9. Xerostomia Therapeutics Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Xerostomia Therapeutics Market
12. Europe Global Xerostomia Therapeutics Market
13. Asia Pacific Global Xerostomia Therapeutics Market
14. Latin America Global Xerostomia Therapeutics Market
15. MEA Global Xerostomia Therapeutics Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Sun Pharmaceuticals Industries Ltd.
- Parnell Pharmaceuticals Inc.
- GlaxoSmithKline plc
- OraCoat
- Colgate-Palmolive Company
- Lupin Pharmaceuticals Inc.
- Pfizer Inc.
- Hikma Pharmaceuticals PLC
- Church & Dwight Co. Inc.
- Acacia Pharma
- Pendopharm
